# Core 2: Chromosome Replication and Analysis (CRA) Core

> **NIH NIH P01** · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · 2024 · $248,376

## Abstract

ABSTRACT
Failure to properly repair DNA double-strand breaks (DSBs) or damaged DNA replication forks leads
to chromosome aberrations and neoplastic transformation of cells. Homology-directed repair (HDR)
mediated by the recombinase RAD51 in conjunction with the tumor suppressors BRCA1-BARD1 and
BRCA2 is a high fidelity mechanism of DSB and replication fork repair. In addition, these HDR factors
also protect stressed DNA replication forks from nucleolytic attrition. The commitment step for HDR
is 5’ strand resection of a DNA end to create a 3’-tailed ssDNA region for the assembly of HDR
complexes that contain RAD51 as a central component. The three Research Projects of this Program
will investigate the biochemical regulation of the DNA end resection and RAD51-ssDNA assembly
steps of HDR and how these processes are negatively regulated by protein factors, such as DNYLL1
and the CTC1-STN1-TEN1 (CST) complex, of the 53BP1 regulatory axis. The Chromosomal and
Replication Analysis (CRA) Core provides valuable shared resourses to help translate biochemical
data into outcomes of DSB repair, replication fork repair and restart, chromosomal stability, mitotic
success, and cellular survival. CRA will create specific mutations in HDR and 53BP1 axis proteins
using CRISPR/Cas9 and generate cell models using RNA interference when gene mutations are
incompatible with viability. The CRA will subject these modified cell lines to DNA fiber analysis, end
resection analysis, cell cycle phase analysis, confocal immunofluorescent microscopy of foci,
isolation of proteins on nascent DNA (iPOND), replication fork fusion/degradation analysis,
cytogenetic and mitotic chromosomal structural analysis and correlate these with cell survival in
replication stress. Our in-depth cellular analyses will permit the three Research Projects to construct
epistatic pathways and, importantly, will help identify new targets for synthetic lethality in inherited
disorders of HDR that lead to breast, ovarian, prostate and other cancers. Such targets are of great
clinical relevance as the vast majority of these cancer patients eventually develop resistance to
currently available synthetic lethal therapy, such as the PARP1 inhibitors. As such, the CRA will bind
the Research Projects together by integrating biochemical data with replication fork, chromosomal,
and cellular outcomes.
1

## Key facts

- **NIH application ID:** 10847792
- **Project number:** 1P01CA275717-01A1
- **Recipient organization:** UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
- **Principal Investigator:** Robert A Hromas
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $248,376
- **Award type:** 1
- **Project period:** 2024-09-01 → 2029-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10847792

## Citation

> US National Institutes of Health, RePORTER application 10847792, Core 2: Chromosome Replication and Analysis (CRA) Core (1P01CA275717-01A1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10847792. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*